Maze Therapeutics (MAZE) Change in Account Payables (2024 - 2026)
Maze Therapeutics (MAZE) posted Change in Account Payables of $2.2 million for Q1 2026, up 296.62% sequentially from -$1.1 million in Q4 2025, and up 282.04% YoY from $579000.0 in Q1 2025.
Maze Therapeutics (MAZE) Change in Account Payables (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Change in Account Payables for 3 years, with the latest figure at $2.2 million in Q1 2026.
- Quarterly Change in Account Payables rose 282.04% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 159.87% YoY) and the FY2025 annual result came in at -$27000.0, up 86.76% from the prior year.
- Change in Account Payables grew to $2.2 million in Q1 2026 per MAZE's latest filing, from -$1.1 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $2.2 million in Q1 2026 and troughed at -$1.2 million in Q3 2024.
- A 3-year average of $220111.1 and a median of $387000.0 in 2024 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 338.27% in 2025, down 237.03% in 2025.
- Over 3 years, Change in Account Payables stood at $821000.0 in 2024, then sank by 237.03% to -$1.1 million in 2025, then jumped by 296.62% to $2.2 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $2.2 million, -$1.1 million, and -$748000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | -1.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.79 Mn |
| Jun 30, 2026 | -1.79 Mn |
| Mar 31, 2026 | 2.21 Mn |
| Mar 31, 2026 | 2.21 Mn |
| Dec 31, 2025 | -1.13 Mn |
| Dec 31, 2025 | -1.13 Mn |
| Sep 30, 2025 | -748,000.00 |
| Sep 30, 2025 | -748,000.00 |
| Jun 30, 2025 | 1.27 Mn |
| Jun 30, 2025 | 1.27 Mn |
| Mar 31, 2025 | 579,000.00 |
| Mar 31, 2025 | 579,000.00 |
| Dec 31, 2024 | 821,000.00 |
| Dec 31, 2024 | 821,000.00 |
| Sep 30, 2024 | -1.17 Mn |
| Sep 30, 2024 | -1.17 Mn |
| Jun 30, 2024 | 387,000.00 |
| Jun 30, 2024 | 387,000.00 |
| Mar 31, 2024 | -243,000.00 |
| Mar 31, 2024 | -243,000.00 |